S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

+0.48 (+1.57%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
67,138 shs
Average Volume
125,157 shs
Market Capitalization
$535.43 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANI Pharmaceuticals logo

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$216.14 million
Cash Flow
$4.88 per share
Book Value
$18.60 per share


Net Income
$-42.60 million
Pretax Margin




Free Float
Market Cap
$535.43 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.75 out of 5 stars

Medical Sector

44th out of 1,424 stocks

Pharmaceutical Preparations Industry

15th out of 681 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.9 5 -4 -3 -2 -1 -

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

Is ANI Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals
or view top-rated stocks.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for ANI Pharmaceuticals

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $0.21. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 6.66% and a negative net margin of 27.78%. During the same quarter last year, the business earned $0.92 earnings per share.
View ANI Pharmaceuticals' earnings history

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided EPS guidance of $1.34-$1.62 for the period, compared to the consensus earnings per share estimate of $1.15. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $292.77 million.

What price target have analysts set for ANIP?

3 analysts have issued 1-year price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $47.00 to $70.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $58.50 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ANI Pharmaceuticals' key executives?
ANI Pharmaceuticals' management team includes the following people:
  • Mr. Nikhil Lalwani, Pres, CEO & Director (Age 44, Pay $2.17M)
  • Mr. Stephen P. Carey, CFO, Sr. VP of Fin. & Corp. Sec. (Age 51, Pay $1.11M)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 59, Pay $709.02k)
  • Mr. Christopher K. Mutz, Head of Rare Disease (Age 50, Pay $643.58k)
  • Mr. Ori Gutwerg, Sr. VP of Generics (Age 48, Pay $710.74k)
  • Mr. Muthusamy Shanmugam MS R.Ph., Head of R&D, COO of Novitium Operations & Director (Age 54)
  • Mr. Chad Gassert, Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Ms. Elizabeth Powell J.D., Chief Compliance Officer & Head of Legal of Rare Disease
  • Dr. Mary Pao M.D., Ph.D., Chief Medical Officer of Rare Disease
What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.73%), Vanguard Group Inc. (4.49%), William Blair Investment Management LLC (3.31%), Dimensional Fund Advisors LP (2.64%), State Street Corp (2.48%) and Thompson Siegel & Walmsley LLC (2.46%). Company insiders that own ANI Pharmaceuticals stock include Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, 1492 Capital Management LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, State Street Corp, Renaissance Technologies LLC, Russell Investments Group Ltd., and Victory Capital Management Inc..
View insider buying and selling activity for ANI Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Thompson Siegel & Walmsley LLC, William Blair Investment Management LLC, Dimensional Fund Advisors LP, Global Alpha Capital Management Ltd., and Vanguard Group Inc.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $31.00.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals has a market capitalization of $535.43 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42.60 million in net income (profit) each year or ($4.530010) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals employs 601 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at [email protected], or via fax at 218-634-3540.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.